ATE177946T1 - Verwendung von l-carnitin und derivaten zur verringerung der toxizität von cyclosporin-a und anderer immunosuppressiva - Google Patents

Verwendung von l-carnitin und derivaten zur verringerung der toxizität von cyclosporin-a und anderer immunosuppressiva

Info

Publication number
ATE177946T1
ATE177946T1 AT95120394T AT95120394T ATE177946T1 AT E177946 T1 ATE177946 T1 AT E177946T1 AT 95120394 T AT95120394 T AT 95120394T AT 95120394 T AT95120394 T AT 95120394T AT E177946 T1 ATE177946 T1 AT E177946T1
Authority
AT
Austria
Prior art keywords
carnitine
immunosuppressants
cyclosporine
toxicity
derivatives
Prior art date
Application number
AT95120394T
Other languages
English (en)
Inventor
Menotti Calvani
Luigi Mosconi
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE177946T1 publication Critical patent/ATE177946T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30—Preparation of optical isomers
    • C07C227/34—Preparation of optical isomers by separation of optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT95120394T 1995-01-20 1995-12-22 Verwendung von l-carnitin und derivaten zur verringerung der toxizität von cyclosporin-a und anderer immunosuppressiva ATE177946T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95RM000037A IT1277147B1 (it) 1995-01-20 1995-01-20 Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.

Publications (1)

Publication Number Publication Date
ATE177946T1 true ATE177946T1 (de) 1999-04-15

Family

ID=11402949

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95120394T ATE177946T1 (de) 1995-01-20 1995-12-22 Verwendung von l-carnitin und derivaten zur verringerung der toxizität von cyclosporin-a und anderer immunosuppressiva

Country Status (13)

Country Link
US (2) US5955424A (de)
EP (1) EP0722724B1 (de)
JP (1) JPH08231390A (de)
KR (1) KR100443730B1 (de)
AT (1) ATE177946T1 (de)
CA (1) CA2167456A1 (de)
DE (1) DE69508551T2 (de)
DK (1) DK0722724T3 (de)
ES (1) ES2130509T3 (de)
GR (1) GR3030545T3 (de)
IT (1) IT1277147B1 (de)
TW (1) TW445145B (de)
ZA (1) ZA96431B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA65587C2 (en) * 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
IT1306179B1 (it) * 1999-07-28 2001-05-30 Sigma Tau Healthscience Spa Composizione per la prevenzione e cura delle disfunzioni e patologierenali di tipo tossico e funzionale.
IT1316998B1 (it) * 2000-03-02 2003-05-26 Sigma Tau Healthscience Spa Composizione per la prevenzione e/o il trattamento degli effetticitotossici indotti dall'uso di agenti immunosoppressori.
MXPA03003230A (es) * 2000-10-12 2004-12-03 Pharma Mar Sa Tratamiento de canceres.
ITRM20010293A1 (it) * 2001-05-29 2002-11-29 Sigma Tau Ind Farmaceuti Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20070087975A1 (en) * 2005-10-17 2007-04-19 Sigma-Tau Industrie Farmaceutiche Riunite Spa Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients
CN102038671B (zh) * 2010-06-29 2012-07-04 辽宁思百得医药科技有限公司 包含左卡尼汀和羟苯磺酸盐的药物组合物
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016099214A1 (ko) * 2014-12-18 2016-06-23 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
IT201900007446A1 (it) * 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
CN115469026B (zh) * 2022-07-14 2023-10-20 中日友好医院(中日友好临床医学研究所) 用于检测环孢素a肾毒性相关标志物的检测试剂、试剂盒及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1195852B (it) * 1986-07-04 1988-10-27 Sigma Tau Ind Farmaceuti Impiego di l-carnitina nel trattamento degli effetti tossici indotti dall'inalazione di alotano e di altri anestitici generali alogenati
JPH01213258A (ja) * 1988-02-23 1989-08-28 Kyowa Hakko Kogyo Co Ltd カルニチンおよびカルニチンアミドの精製法

Also Published As

Publication number Publication date
JPH08231390A (ja) 1996-09-10
DE69508551D1 (de) 1999-04-29
EP0722724B1 (de) 1999-03-24
TW445145B (en) 2001-07-11
KR960029314A (ko) 1996-08-17
GR3030545T3 (en) 1999-10-29
ITRM950037A0 (it) 1995-01-20
CA2167456A1 (en) 1996-07-21
IT1277147B1 (it) 1997-11-04
KR100443730B1 (ko) 2004-10-14
ITRM950037A1 (it) 1996-07-20
ES2130509T3 (es) 1999-07-01
DE69508551T2 (de) 1999-09-02
EP0722724A1 (de) 1996-07-24
US5958941A (en) 1999-09-28
ZA96431B (en) 1996-08-08
DK0722724T3 (da) 1999-10-11
US5955424A (en) 1999-09-21

Similar Documents

Publication Publication Date Title
CA2216796A1 (en) Quinazoline derivatives
ATE177946T1 (de) Verwendung von l-carnitin und derivaten zur verringerung der toxizität von cyclosporin-a und anderer immunosuppressiva
DE69841367D1 (de) Peptidderivate oder deren pharmazeutisch annehmbare salze, verfahren zu deren herstellung, verwendung dieser derivate und arzneimittel
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
CA2183655A1 (en) 4-polycyclic amino-substituted quinazoline derivatives
ES2052717T3 (es) Uso de derivados de indolona para la preparacion de medicamentos para el tratamiento de la enfermedad de parkinson.
RU95108759A (ru) Фармацевтические соединения
DE69713148D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
DE69713152D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
RU93004793A (ru) Производные хиназолина, способ их получения, фармацевтическая композиция на их основе
EP0485636A4 (en) Indole derivative
ATE146780T1 (de) Verbindungen mit guanidin-struktur und diese enthaltende pharmazeutische zusammensetzungen
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
AU3636089A (en) Hydrazine derivatives for pharmaceutical use
ZA9110037B (en) The use of acetyl l-carnitine in the therapeutic treatment of coma and pharmacological compositions useful in such treatment
NO923721L (no) 4-desoksy-4-epipodophyllotoxin-derivat eller farmasoeytiskakseptabelt salt derav
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
DE68926972T2 (de) Thienotriazoldiazepinverbindungen und deren pharmazeutische Anwendungen
DE68919378D1 (de) Thienotriazolodiazepine und ihre pharmazeutische Verwendung.
MX9405209A (es) Uso de las n-(piridinil)-1h-indol-1-aminas en la preparacion de unmedicamento para el tratamiento de desordenes obsesivo-compulsivos.
DE69412612D1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
ATE177632T1 (de) Antineoplastische pharmazeutische zusammensetzung enthaltend ein fumagillolderivat und einen platinkomplex
MX9605131A (es) Formulacion estable de lactona de 7-etil-camptotecina y metodo para usar la misma.
ATE125807T1 (de) Flavonderivate.
SE8802997L (sv) Aminderivat och dess salt, foerfarande foer framstaellning daerav och medel mot saar innehaallande desamma

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee